Current Report Filing (8-k)
September 14 2017 - 1:33PM
Edgar (US Regulatory)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
September 14, 2017
Atossa Genetics Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-35610
|
|
26-4753208
|
(State or other jurisdiction of
incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
107 Spring Street
Seattle, Washington
|
|
98104
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (206) 325-6086
Not Applicable
Former name or former address, if changed since
last report
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01. Regulation FD Disclosure
On September 14, 2017, Atossa Genetics Inc. (the “Company”)
issued a press release announcing preliminary results from its Phase 1 study of topical Endoxifen. Also on September 14, 2017,
the Company plans to hold a conference call and present information about the preliminary results from the Phase 1 study of topical
Endoxifen. A copy of the press release and slides for the conference call are attached as Exhibit 99.1 and 99.2, respectively,
to this current report and are incorporated herein by reference.
* * *
The Company is furnishing the information in this Current Report
on Form 8-K to comply with Regulation FD. Such information shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be
deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation
language in such filings, except to the extent expressly set forth by specific reference in such a filing.
“Safe harbor” statement under the Private Securities
Litigation Reform Act of 1995: Some of the information presented herein may contain projections or other forward-looking statements
regarding future events or the future financial performance of the Company, which the Company undertakes no obligation to update.
These statements are based on management’s current expectations and are subject to risks and uncertainties that may cause
actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated
with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical
trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market
demand for and acceptance of the Company’s products and services, performance of clinical research organizations and other
risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission, including without
limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended
and supplemented from time to time.
Item 8.01 Other Events.
See item 7.01 above which is incorporated into this Item 8.01 by
this reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit No.
|
|
Description
|
99.1
99.2
|
|
Press Release, dated September 14, 2017
Topical Endoxifen Slide Presentation, dated September 14, 2017
|
|
|
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 14, 2017
|
Atossa Genetics Inc.
|
|
|
|
|
|
By:
|
/s/ Kyle Guse
|
|
|
|
Kyle Guse
|
|
|
|
Chief Financial Officer, General Counsel and Secretary
|
|
Exhibit Index
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024